title: Overactive bladder: recognition requires vigilance for symptoms.
abstract: Overactive bladder (OAB) is a prevalent condition in both men and women that imposes significant burdens on the patient and his or her quality of life. Nevertheless, only a small percentage of patients with OAB receive diagnosis and treatment. The identification of OAB is well within the scope of the primary care provider, as it is symptom-based and does not generally require specialized testing. The treatment of OAB relies on behavioral modification and/or pharmacologic options, primarily antimuscarinic therapy. Better identification of OAB symptoms in the primary care setting should reduce the number of patients suffering from untreated OAB.
authors.affiliation: Mid-Michigan Health Centers, Jackson, MI 49201, USA. matttoren@yahoo.com
authors.forename: Matt T
authors.initials: MT
authors.lastname: Rosenberg
authors.forename: Diane K
authors.initials: DK
authors.lastname: Newman
authors.forename: Christopher T
authors.initials: CT
authors.lastname: Tallman
authors.forename: Shari A
authors.initials: SA
authors.lastname: Page
mesh_terms: D001559:Benzhydryl Compounds / Q000627:therapeutic use; D017281:Cost of Illness; D003408:Cresols / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008297:Male; D008333:Mandelic Acids / Q000627:therapeutic use; D008403:Mass Screening; D018727:Muscarinic Antagonists / Q000627:therapeutic use; D010665:Phenylpropanolamine / Q000627:therapeutic use; D015995:Prevalence; D011788:Quality of Life; D000068737:Tolterodine Tartrate; D053201:Urinary Bladder, Overactive / Q000175:diagnosis* / Q000188:drug therapy / Q000453:epidemiology / Q000209:etiology
chemical_list: D001559:Benzhydryl Compounds; D003408:Cresols; D008333:Mandelic Acids; D018727:Muscarinic Antagonists; D010665:Phenylpropanolamine; D000068737:Tolterodine Tartrate; C005419:oxybutynin